SCHEMBL426470

SCHEMBL426470

COc1ccc(-c2cn(C(=O)N(C)c3ccc(F)cc3C)cn2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STS P08842 1/20 0.43
HSD17B1 P14061 1/20 0.42
HSD17B2 P37059 1/20 0.42
PLA2G2A P14555 1/20 0.40
ABL1 P00519 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
SCN4A P35499 1/20 0.38
FAAH O00519 1/20 0.37
MAPT P10636 4/20 0.37
RXFP1 Q9HBX9 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.37
MAPK1 P28482 1/20 0.37
KMT2A Q03164 1/20 0.37
GRIN2B Q13224 1/20 0.37
HTT P42858 1/20 0.37
BCR P11274 1/20 0.37
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL425556 0.84 L3MBTL1 (0.43) PLA2G2AABL1L3MBTL1SCN4AFAAH
SCHEMBL426694 0.77 ACHE (0.49) L3MBTL1FAAHMAPTSMN1; SMN2LMNA
SCHEMBL425544 0.75 FAAH (0.52) FAAHMAPTHTTALDH1A1
SCHEMBL425965 0.73 FAAH (0.61) FAAHKMT2AGRIN2BNPC1RAB9A
SCHEMBL425399 0.72 RAB9A (0.43) FAAHMAPTSMN1; SMN2MEN1LMNA
SCHEMBL425992 0.72 FAAH (0.62) FAAHSMN1; SMN2MEN1KMT2AGRIN2B
SCHEMBL425550 0.72 FAAH (0.51) SCN4AFAAHMAPTSMN1; SMN2MEN1
SCHEMBL427152 0.71 FAAH (0.42) SCN4AFAAHMEN1LMNAMAPK1
SCHEMBL425329 0.70 FAAH (0.50) FAAHSMN1; SMN2MEN1KMT2AGRIN2B
SCHEMBL426156 0.70 FAAH (0.50) FAAHGRIN2BHTTNPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 STS 971/4885HSD17B1 555/4885HSD17B2 646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.